Insights

Niche Therapeutics Targeting niche CNS delivery via chitosan-based nanoparticles presents a specialized opportunity for partnerships with larger biotech firms and academic collaborators exploring neurodegenerative therapy and antibody/small molecule delivery across the nasal route.

SBIR Funded Validation NIH SBIR Phase II funding and multiple project milestones underscore credible early-stage validation, signaling potential for co-development deals, sponsorships, and grant-aligned collaborations with larger entities seeking FDA-ready or near-term translational assets.

Nose-to-Brain Platform Non-viral nose-to-brain delivery platform for nucleic acids or small molecules aligns with growing demand for non-invasive CNS therapeutics, offering a compelling value proposition for strategic partners in neurology, geriatrics, and biotech ventures pursuing brain-targeted therapies.

Clinical & Disease Focus Focus on cerebral amyloid angiopathy and Alzheimer's-related pathology provides a clear market narrative for potential partners in neurology pharma, contract research organizations, and academic consortia aiming to accelerate CNS therapeutic pipelines.

Strategic Partnerships Small team size with significant externally funded programs suggests readiness for licensing, joint ventures, or sponsored research with larger conglomerates seeking early-stage assets to diversify their CNS portfolios and accelerate time to value.

Similar companies to Karamedica, Inc.

Karamedica, Inc. Tech Stack

Karamedica, Inc. uses 8 technology products and services including Open Graph, WordPress, Shopify, and more. Explore Karamedica, Inc.'s tech stack below.

  • Open Graph
    Content Management System
  • Content Management System
  • E-commerce
  • Modernizr
    Javascript Libraries
  • Select2
    Javascript Libraries
  • PHP
    Programming Languages
  • Nginx
    Web Servers

Karamedica, Inc.'s Email Address Formats

Karamedica, Inc. uses at least 1 email format:
Karamedica, Inc. Email FormatsExamplePercentage
First.Last@karamedica.comJohn.Doe@karamedica.com
100%

Frequently Asked Questions

What is Karamedica, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Karamedica, Inc.'s official website is karamedica.com and has social profiles on LinkedIn.

How much revenue does Karamedica, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Karamedica, Inc.'s annual revenue is estimated to be $1M - $10M.

What is Karamedica, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Karamedica, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Karamedica, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Karamedica, Inc. has approximately 5 employees across 1 continents, including North America. Key team members include Chief Financial Officer: T. S., Chief Scientific Officer: S. H. and President & Ceo: A. C. Explore Karamedica, Inc.'s employee directory with LeadIQ.

What industry does Karamedica, Inc. belong to?

Minus sign iconPlus sign icon
Karamedica, Inc. operates in the Biotechnology Research industry.

What technology does Karamedica, Inc. use?

Minus sign iconPlus sign icon
Karamedica, Inc.'s tech stack includes Open Graph, WordPress, Shopify, Google Workspace, Modernizr, Select2, PHP and Nginx.

What is Karamedica, Inc.'s email format?

Minus sign iconPlus sign icon
Karamedica, Inc.'s email format typically follows the pattern of First.Last@karamedica.com. Find more Karamedica, Inc. email formats with LeadIQ.

When was Karamedica, Inc. founded?

Minus sign iconPlus sign icon
Karamedica, Inc. was founded in 2016.
Karamedica, Inc. logo

Karamedica, Inc.

Biotechnology ResearchNorth Carolina, United States2-10 Employees

Karamedica, Inc. is a biotechnology research company focused on expanding the use of biopolymer-based delivery systems, including chitosan, for therapeutic applications. Its work centers on developing a non-viral, nose-to-brain delivery platform for nucleic acids or small molecules, supported by NIH funding, to address neurological conditions. The company aims to translate these delivery approaches into treatments that can reach the brain via the nasal route, potentially enabling targeted therapeutic effects. Based in Raleigh, North Carolina, Karamedica operates as a small, research-oriented organization in the biotech sector, pursuing early-stage applications in cerebral conditions.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
2-10

Section iconFunding & Financials

  • $1M - $10M

    Karamedica, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.